Skip to main content
Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · Real-Time Price · USD
3.770
+0.090 (2.45%)
Nov 13, 2026, 4:00 PM EST - Market closed

Fulcrum Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
--802.816.3419.16
Revenue Growth
--2752.05%-55.77%-66.91%117.19%
Gross Profit
-44.98-56.116.61-69-70.44-50.54
Operating Income
-76.25-84.77-19.83-110.66-112.13-81.05
Net Income
-76.34-74.88-9.73-97.34-109.87-80.85
Earnings Per Share
-1.04-1.18-0.16-1.59-2.44-2.29
EPS Growth
------

Cash & Debt
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
306.55352.31241.02236.22202.92218.16
Total Debt
6.836.448.6310.8213.42-
Net Cash (Debt)
299.72345.86232.39225.4189.5218.16
Net Cash Growth
54.79%48.83%3.10%18.95%-13.14%93.24%
Net Cash Per Share
4.075.463.753.684.216.17

Cash Flow & CapEx
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-64.97-60.07-2.22-90.97-97.05-78.48
Capital Expenditures
-0.28-0.31-0.28-0.51-1.96-1.71
Free Cash Flow
-65.24-60.38-2.5-91.47-99.01-80.19
Free Cash Flow Growth
------

Margins
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
--20.77%---263.73%
Operating Margin
---24.79%-3945.24%-1768.12%-422.97%
Pretax Margin
---12.16%-3470.05%-1732.43%-421.89%
Profit Margin
---12.16%-3470.05%-1732.43%-421.89%
FCF Margin
---3.12%-3261.07%-1561.23%-418.47%

Valuation
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
--3.17148.7759.7537.41